Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32.

@article{Stanley2013DiarylcoumarinsIM,
  title={Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32.},
  author={Sarah A Stanley and Tomohiko Kawate and Noriaki Iwase and Motohisa Shimizu and Anne E Clatworthy and Edward Kazyanskaya and James C. Sacchettini and Thomas R. Ioerger and Noman A Siddiqi and Shoko Minami and John A Aquadro and Sarah Schmidt Grant and Eric J. Rubin and Deborah T Hung},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2013},
  volume={110 28},
  pages={11565-70}
}
Infection with the bacterial pathogen Mycobacterium tuberculosis imposes an enormous burden on global public health. New antibiotics are urgently needed to combat the global tuberculosis pandemic; however, the development of new small molecules is hindered by a lack of validated drug targets. Here, we describe the identification of a 4,6-diaryl-5,7-dimethyl coumarin series that kills M. tuberculosis by inhibiting fatty acid degradation protein D32 (FadD32), an enzyme that is required for… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening

  • SA Stanley
  • ACS Chem Biol
  • 2012

Similar Papers

Loading similar papers…